Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) Director Jeffrey Leiden acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were bought at an average price of $20.00 per share, with a total value of $100,000.00. Following the completion of the transaction, the director directly owned 270,198 shares in the company, valued at approximately $5,403,960. The trade was a 1.89% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Odyssey Therapeutics Price Performance
ODTX stock opened at $17.94 on Thursday. Odyssey Therapeutics, Inc. has a 1 year low of $15.35 and a 1 year high of $20.30.
Read More
- Five stocks we like better than Odyssey Therapeutics
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
